Mary Feng

Mary Feng

Mary Feng, M.D.

Vice Chair for Clinical Research

Associate Professor
Department of Radiation Oncology

University of California, San Francisco
Gateway Medical Building
Box 4001, 1825 Fourth Street, Suite M2267
San Francisco, CA 94158
Phone: 415 502-7222
Fax: 415 476-7370
TTY: 415 885-3889

 

 

 

Professional Focus

Dr. Mary Feng specialized in treatment of gastrointestinal and hepatobiliary cancers. Her research focuses on technical and biological methods to individualize and adapt radiotherapy for each patient with pancreas and liver cancer to maximize the effectiveness of treatment. Her primary goals are 1) Improving outcomes for patients with pancreas and liver cancer through novel combination treatments; 2) Adapting radiotherapy based on early blood and imaging biomarkers of tumor response and treatment effects on nearby organs; and 3) Evaluating the use of advanced technologies in radiotherapy.

Dr. Feng is Vice-Chair for Clinical Research, Clinical site director for the Mission Bay Clinic, and Director of Quality Assurance and Safety for the Department of Radiation Oncology at UCSF. She also serves on numerous national and international cancer organization panels and groups, including the National Comprehensive Cancer Network Pancreatic Adenocarcinoma Panel, the American Society of Clinical Oncology Gastrointestinal Cancer Guideline Advisory Group, and the American Society for Radiation Oncology IHE-RO Clinical Advisory Subcommittee as co-chair.

 

Education

1993-1997 Stanford University BS Honors in Biological Sciences
1998-2002 Washington University School of Medicine MD  
2002-2003 University of Michigan Medical Center, Ann Arbor Preliminary Medical Intern  
2003-2006 University of Michigan Medical Center, Ann Arbor Resident Radiation Oncology
2006-2007 University of Michigan Medical Center, Ann Arbor Chief Resident Radiation Oncology

 

Professional Experience

  PRINCIPAL POSITIONS HELD    
2007-2009 University of Michigan, Ann Arbor Clinical Instructor Radiation Oncology
2009-2013 University of Michigan, Ann Arbor Clinical Assistant Professor Radiation Oncology
2011-2016 University of Michigan, Ann Arbor Medical Director, MRI Program Radiation Oncology
2012-2016 University of Michigan, Ann Arbor Associate Director of Clinical Research Radiation Oncology
2013-2016 University of Michigan, Ann Arbor Clinical Associate Professor Radiation Oncology
2016-present University of California, San Francisco Vice Chair for Clinical Research Radiation Oncology
2016-present University of California, San Francisco Associate Professor Radiation Oncology

 

Awards & Honors

1996 Howard Hughes Medical Institute Summer Research Fellowship, Stanford University
1998 American Red Cross Volunteer of the Year, Palo Alto, California chapter
1998 Philpott Scholarship, Washington University School of Medicine
1999 Mallinckrodt Institute/Howard Hughes Medical Institute Summer Radiation Oncology Fellowship
2004 Third place presentation, Michigan Society of Therapeutic Radiation Oncology Resident Research Competition
2005 American Association for Women Radiologists Member-in-Training Award for Outstanding RSNA Presentation in Radiation Oncology
2006 American Association for Women Radiologists Member-in-Training Award for Outstanding ASTRO Presentation in Radiation Oncology
2007 Radiological Society of North America, Resident Research and Education Foundation Award
2007 American Society for Radiation Oncology plenary session presentation; abstract selected from 2036 total submissions from around the world.
2013 Two abstracts selected for presentation at the 2013 Best of ASTRO conference

 

Recent Significant Publications :

Cuneo KC, Chenevert TL, Ben-Josef E, Feng M, Greenson JK, Hussain HK, Simeone DM, Schipper JM, Anderson MA, Zalupski MM, Al-Hawary M, Galgan CJ, Rehemtulla A, Feng FY, Lawrence TS, Ross BD. A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer. Transl Oncol 2014;7(5):644-9. PMIC 25389460, PMCID: 4225651

Cuneo KC, Davis MA, Feng M, Novelli PM, Ensminger WD, Lawrence TS. Low dose rate radiosensitization of hepatocellular carcinoma in vitro and in patients. Transl Oncol 2014;7(4):472-8. PMID: 24956939, PMCID: 4202782

Jagsi R, Griffith, KA, Heimburger D, Walker EM, Grills IS, Boike T, Feng M, Moran JM, Hayman J, Pierce LJ. Choosing Wisely? Patterns and correlates of the use of hypofractionated whole-breast radiation therapy in the state of Michigan. Int. J. Rad. Onc. Biol. Phys 2014;90(5):1010-1016. PMID: 25539366

Hsu SH, Cao Y, Lawrence TS, Tsien C, Feng M, Grodzki DM, Balter JM. Quantitative characterizations of ultrashort echo (UTE) images for supporting air-bone separation in the head. Phys Med Biol 2015;60(7):28692880. PMID: 25776205

Shumway D, Griffith KA, Pierce LJ, Feng M, Moran JM, Stenmark MH, Jagsi R, Hayman JA. Wide variation in the diffusion of a new technology: Practice-based trends in intensity modulated radiation therapy (IMRT) utilization in the state of Michigan with implications for IMRT use nationally. J Oncol Pract 2015;11(3):e373-379. PMID: 25736383

Davis EJ, Chugh R, Zhao L, Lucas DR, Biermann JS, Zalupski MM, Feng M, Wong SL, Jacobson J, Zyczynski L, Reinke D, Metko G, Baker LH, Schuetze SM. A randomized, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localized, high-risk, soft tissue sarcoma. European J of Cancer 2015;51(13):1794-1802. PMID: 26066736

Jagsi R, Griffith KA, Boike TP, Walker E, Nurushev T, Grills IS, Moran JM, Feng M, Hayman J, Pierce LJ. Differences in the acute toxic effects of breast radiotherapy by fractionation schedule: Comparative analysis of physician-assessed and patient-reported outcomes in a large multicenter cohort. JAMA Oncol. 2015;1(7):918-30. doi: 10.1001/jamaoncol.2015.2590. PubMed PMID: 26247417

Zhou J, Fang CX, Shen J, Schipper JM, Zalupski MM, Minter RM, Simeone DM, Hart D, Eagle T, Kimmel GW, Vainshtein J, Lawrence TS, Feng M. Definitive chemoradiation with full-dose gemcitabine for unresectable pancreatic cancer: Efficacy of involved field radiotherapy. Am J Clin Oncol. 2015. doi: 10.1097/COC.0000000000000200. PubMed PMID: 26165418.

Wahl DR, Stenmark MH, Tao Y, Pollom E, Caoili EM, Lawrence TS, Schipper MJ, Feng M. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol. 2016;34(5):452-9. doi: 10.1200/JCO.2015.61.4925. PubMed PMID: 26628466; PMCID: PMC4872011

Paradis E, Cao Y, Lawrence TS, Tsien C, Feng M, Vineberg K, Balter JM. Assessing the dosimetric accuracy of magnetic resonance-generated synthetic CT images for focal brain VMAT radiation therapy. Int J Radiat Oncol Biol Phys. 2015;93(5):1154-61. doi: 10.1016/j.ijrobp.2015.08.049. PubMed PMID: 26581151; PMCID: PMC4654706

Matuszak MM, Hadley SW, Feng M, Hayman JA, Brock KK, Burger P, Owen D, Suresh K, Lawrence TS, Ten Haken RK. Enhancing safety and quality through pre-planning peer review for patients undergoing stereotactic body radiation therapy. Pract Radiat Oncol. 2016;6(2):e39-46. doi: 10.1016/j.prro.2015.09.009. PubMed PMID: 26746815